Unknown PHASE2 INTERVENTIONAL 2-arm NCT01461720

Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct

An Open Lable, Phase II Exploratory Study Assessing the Efficacy of Intravenous Autologous Mesenchymal Stem Cells in Patients With Middle Cerebral Artery Infarct

Sponsor: Cytopeutics Sdn. Bhd.

Conditions Middle Cerebral Artery Infarction

Interventions Autologous bone marrow-derived mesenchymal stem cells Standard medical care

Updated 7 times since 2017 Last updated: Mar 30, 2015 Started: Mar 31, 2012 Primary completion: Dec 31, 2015 Completion: Mar 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Middle Cerebral Artery Infarction and is currently ongoing. Cytopeutics Sdn. Bhd. leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Feb 2019 — Jan 2021 [monthly]

Unknown Status PHASE2
Jun 2018 — Feb 2019 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

May 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2017 — May 2017 [monthly]

Recruiting PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cytopeutics Sdn. Bhd.
National University of Malaysia

Data source: National University of Malaysia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kuala Lumpur, Malaysia